publication date: Oct. 19, 2018

Clinical Roundup Keytruda-Inlyta combination improved OS and PFS in front line for advanced, metastatic RCC

The pivotal phase III KEYNOTE-426 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), Pfizer’s tyrosine kinase inhibitor, met both primary endpoints of overall survival and progression-free survival in the first-line treatment of advanced or metastatic renal cell carcinoma.

Based on the first interim analysis by the independent Data Monitoring Committee, the Keytruda plus Inlyta combination resulted in statistically significant and clinically meaningful improvements in OS and PFS, compared to sunitinib monotherapy.

The study also met the key secondary endpoint of objective response rate, with significant improvements for the Keytruda and Inlyta combination compared with sunitinib monotherapy. Results for OS, PFS and ORR were consistent regardless of PD-L1 expression and across all risk groups.

The safety profile of Keytruda and Inlyta in this trial was generally consistent with that observed in previously reported studies for each therapy. These results will be presented at an upcoming medical meeting and submitted to regulatory authorities worldwide.

“This marks the first time that combination treatment with an anti-PD-1 therapy has achieved the dual primary endpoints of overall survival and progression-free survival as first-line therapy in advanced renal cell carcinoma,” said Roger Perlmutter, president, Merck Research Laboratories. “We are very grateful … Continue reading Keytruda-Inlyta combination improved OS and PFS in front line for advanced, metastatic RCC

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.